BSE: 524210
PENTOKEY ORGANY (INDIA) LTD.
Trades pharmaceutical products and, more recently, fertilizers and pesticides on BSE (Scrip Code 524210). FY26 revenue from operations came in at ₹209 lakh, up from ₹82.62 lakh in FY25, with the trading push reflected in H1 FY26 half-year revenue of ₹604.54 lakh before large sales returns or reversals in Q3 FY26 pulled quarterly revenue into negative territory. Net profit for FY26 was ₹20.32 lakh, down from ₹24.55 lakh the prior year, as employee costs of 7.7% of revenue and other operating expenses of 9.8% absorbed most of the trading margin. Materials and depreciation were reported at 0% of revenue, consistent with a pure trading model rather than any manufacturing activity. On the balance sheet, total equity stood at ₹969.52 lakh with cash and bank balances above ₹604 lakh and minimal debt, while trade receivables spiked to ₹675.98 lakh and trade payables rose to ₹453 lakh by H1 FY26 alongside the trading scale-up. The company has a small paid-up equity base of ₹627.26 lakh, a net worth of ₹915.72 lakh as of March 2025, and around 9,390 shareholders on record. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical products trading, Fertilizers and pesticides trading. Small, asset-light commodity/chemical trading company with volatile quarterly results and large swings in trade receivables.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 4 | 4 | 1 | 2 |
| EBITDA (ex other income) | (0) | 1 | 0 | (0) | (0) |
| margin % | — | 19.5 | 9.8 | (26.2) | (9.8) |
| Owners' profit | (0) | 3 | 1 | 0 | 0 |
| EPS, as reported (₹) | (0.26) | 5.06 | 1.39 | 0.39 | 0.38 |
| ROE % · ROCE % | (3.1) · (3.1) | 37.9 · 38.2 | 9.4 · 9.5 | 2.6 · 2.6 | 2.1 · 2.1 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | (0.00) |
| Cash from operations | (0) | (0) | 1 | 0 | 1 |
| Capex | 0 | 0 | 0 | 0 | 0 |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 | 5 | 1 | (2) | (2) |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | (0) | (0) |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | (0) | (0) |
| EPS (₹) | 0.07 | 0.17 | 0.06 | 0.09 | 0.99 | 0.23 | 23.72 | 0.46 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| TATA CHEMICALS LTD | 15,351 | — | 0.69 | 139.2 | (7.7) | (5.0) | 7.4 | 14.4 |
| DEEPAK FERTILIZERS & PETR | 14,679 | 14.9 | 1.97 | 11.1 | 9.9 | 8.4 | 14.6 | 26.1 |
| GUJ NAR VAL FER & CHEM L | 7,529 | 7.3 | 0.83 | 5.4 | 8.9 | 10.3 | 8.7 | 22.1 |
| TANFAC INDUSTRIES LTD. | 6,923 | 56.6 | 18.55 | — | 18.8 | 24.3 | — | 16.0 |
| GUJARAT ALKALIES & CHEM | 4,105 | 61.8 | 0.79 | 8.7 | (0.0) | 0.7 | 12.4 | 18.4 |
| GHCL LIMITED | 3,565 | 7.8 | 1.00 | 4.7 | 13.3 | 16.6 | 1.1 | 23.9 |
| GRAUER & WEIL IND LTD | 3,543 | 21.6 | 3.28 | 14.4 | 15.2 | 19.2 | 14.5 | 20.4 |
| J.G.CHEMICALS LIMITED | 2,179 | 29.0 | 4.03 | 22.2 | 12.7 | 16.9 | — | 11.5 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 1.2 | 17.4 | 3 of 50 | 96% |
| P/B | 2.0 | 1.4 | 37 of 60 | 39% |
| ROCE | 2.1 | 6.0 | 42 of 62 | 33% |
| ROE | 2.1 | 5.0 | 39 of 60 | 36% |
| Debt / Equity | 0.0 | 0.2 | 1 of 60 | 100% |
| EBITDA margin | 7.0 | 13.3 | 38 of 58 | 35% |
| Revenue growth | (407.5) | 6.7 | 54 of 54 | 0% |
| Profit growth | (332.6) | 21.0 | 61 of 64 | 5% |
| Market cap | 19 | 98 | 50 of 66 | 25% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 15 Oct 2026 · RTA compliance certificate filed for Q2 FY27 under SEBI Reg 74(5) | compliance | minimal | — | — |
| 14 Oct 2026 · Trading window closed until Q2 FY26 results are announced | compliance | minimal | — | — |
| 28 Sept 2026 · Intimation under regualtion 44 of SEBI LODR and consolidated Scrutinizer report on voting done through remote e voting and e voting at 39th AGM held on 26th September, 2026 is attached. | board shareholder meetings | low | — | — |
| 26 Sept 2026 · Pentokey Organy holds 39th AGM via video conferencing | board shareholder meetings | low | — | — |
| 6 Sept 2026 · Newspaper ad copies for 39th AGM filed with BSE | compliance | minimal | — | — |
| 3 Sept 2026 · Annual Report FY26 and 39th AGM notice filed with BSE | results | high | — | — |
| 13 Aug 2026 · AGM scheduled for 26 September 2026 via video conference | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Pentokey Organy appoints Ms Kavita Bohra as Independent Director | management changes | medium | — | — |
| 13 Aug 2026 · Q1 FY27 revenue up 153% YoY but profit dips 11% | results | high | — | — |
| 13 Aug 2026 · Pentokey Organy Q1 FY27 Results: PAT Rs 21.73 lakh, Revenue Rs 209 lakh | results | medium | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.